Jorge Luis Sanchez Bibiloni

Mr. Jorge Luis Sanchez Bibiloni


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 October 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAngel Emmanuel Miranda Santiago
Angel Emmanuel Miranda Santiago
CSCrisanta Serrano
Crisanta Serrano
LCLorna A. Cruz
Lorna A. Cruz
SHSandra Henein
Sandra Henein
LALaura Alvarez
Laura Alvarez
CSCarlos A. Sariol
Carlos A. Sariol
Background: Understanding the immune mechanisms that differentiate protective from pathogenic responses during dengue virus (DENV) infection is critical for effective vaccine development. Objective: To investigate how CD4+ T cell depletion alters viral control and the humoral immune response during primary DENV2 infection in a non-human primate (NHP) model. Methods: Rhesus macaques were depleted of CD4+ T cells prior to DENV2 infection. Viral kinetics, B cell activation, antibody specificity, and functional outcomes were evaluated longitudinally, including cross-reactivity and antibody-dependent enhancement (ADE) potential. Results: CD4+ T cells were essential for early viral clearance and the generation of robust, type-specific neutralizing antibodies. In their absence, animals exhibited early non-specific polyclonal B cell activation, delayed isotype switching, and an expanded repertoire of cross-reactive antibodies to DENV and Zika virus (ZIKV), with diminished neutralizing capacity. CD4-depleted macaques also showed increased ADE potential, particularly against ZIKV, and elevated anti-NS1 IgG titers that persisted one-year post-infection. Conclusion: CD4+ T cells play a critical role in orchestrating effective, durable, and type-specific antibody responses during primary DENV infection. Their absence leads to delayed antibody maturation, greater cross-reactivity, and higher ADE potential. These findings emphasize the need for DENV and ZIKV vaccines to include CD4+ T cell epitopes that promote high-quality, type-specific antibody responses and minimize ADE risk.

13 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAngel Emmanuel Miranda Santiago
Angel Emmanuel Miranda Santiago
CSCrisanta Serrano
Crisanta Serrano
LCLorna A. Cruz
Lorna A. Cruz
SHSandra Henein
Sandra Henein
LALaura Alvarez
Laura Alvarez
CSCarlos A. Sariol
Carlos A. Sariol
Background: Understanding the immune mechanisms that differentiate protective from pathogenic responses during dengue virus (DENV) infection is critical for effective vaccine development. Objective: To investigate how CD4+ T cell depletion alters viral control and the humoral immune response during primary DENV2 infection in a non-human primate (NHP) model. Methods: Rhesus macaques were depleted of CD4+ T cells prior to DENV2 infection. Viral kinetics, B cell activation, antibody specificity, and functional outcomes were evaluated longitudinally, including cross-reactivity and antibody-dependent enhancement (ADE) potential. Results: CD4+ T cells were essential for early viral clearance and the generation of robust, type-specific neutralizing antibodies. In their absence, animals exhibited early polyclonal B cell activation, delayed isotype switching, and an expanded repertoire of cross-reactive antibodies to DENV and Zika virus (ZIKV), with diminished neutralizing capacity. CD4-depleted macaques also showed increased ADE potential, particularly against ZIKV, and elevated anti-NS1 IgG titers that persisted one-year post-infection. Conclusion: CD4+ T cells play a critical role in orchestrating effective, durable, and type-specific antibody responses during primary DENV infection. Their absence leads to delayed antibody maturation, greater cross-reactivity, and higher ADE potential. These findings emphasize the need for dengue and Zika vaccines to include CD4+ T cell epitopes that promote high-quality, type-specific antibody responses and minimize ADE risk.